Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.

Chen J, Shao R, Li L, Xu ZP, Gu W.

Int J Nanomedicine. 2014 Jul 16;9:3403-11. doi: 10.2147/IJN.S61633. eCollection 2014.

2.

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.

Zou H, Li L, Garcia Carcedo I, Xu ZP, Monteiro M, Gu W.

Int J Nanomedicine. 2016 May 5;11:1947-58. doi: 10.2147/IJN.S100744. eCollection 2016.

3.

Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.

Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC.

Mol Pharmacol. 2015 Sep;88(3):512-23. doi: 10.1124/mol.115.099143. Epub 2015 Jun 22.

4.

Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.

Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.

Clin Cancer Res. 2011 Oct 15;17(20):6482-9. doi: 10.1158/1078-0432.CCR-11-0933. Epub 2011 Aug 10.

5.

PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.

Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP, Gu W.

Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1317-26. doi: 10.1111/1440-1681.12493.

PMID:
26399781
6.

Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.

Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, Soong R.

Cancer Biol Ther. 2012 Jan 1;13(1):34-42. doi: 10.4161/cbt.13.1.18437.

PMID:
22336586
8.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

10.

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1601-15. doi: 10.1007/s00280-012-1869-z. Epub 2012 Apr 29.

PMID:
22543857
11.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.

Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM.

Cancer Lett. 2015 Feb 28;357(2):582-90. doi: 10.1016/j.canlet.2014.12.015. Epub 2014 Dec 10.

PMID:
25497009
12.

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.

Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.

Int J Mol Med. 2013 Jun;31(6):1449-56. doi: 10.3892/ijmm.2013.1351. Epub 2013 Apr 16.

PMID:
23588698
13.

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Fröhling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.

Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. Epub 2014 Oct 17.

PMID:
25322685
14.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.

Br J Cancer. 2014 May 13;110(10):2479-88. doi: 10.1038/bjc.2014.220. Epub 2014 Apr 24.

15.

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.

Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN.

Mol Cancer Ther. 2013 May;12(5):577-88. doi: 10.1158/1535-7163.MCT-12-0862. Epub 2013 Feb 27.

16.

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.

Zhang CΗ, Awasthi N, Schwarz MA, Schwarz RE.

Int J Oncol. 2013 Nov;43(5):1627-35. doi: 10.3892/ijo.2013.2099. Epub 2013 Sep 13.

17.

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.

Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N, Gao J, Shen L.

BMC Cancer. 2015 Nov 11;15:894. doi: 10.1186/s12885-015-1900-y.

18.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

19.

Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.

Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ, Ko JL.

Toxicol Lett. 2013 Jul 18;220(3):267-76. doi: 10.1016/j.toxlet.2013.04.021. Epub 2013 May 4.

PMID:
23651616
20.

Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.

Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.

Mol Cancer Res. 2013 Oct;11(10):1269-78. doi: 10.1158/1541-7786.MCR-13-0212. Epub 2013 Jun 27.

Supplemental Content

Support Center